Pure Global AI
NCT05683171Not yet recruiting

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

M.D. Anderson Cancer CenterPhase 1/2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Lymphoma
Drug/Device/Intervention
Rituximab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
M.D. Anderson Cancer Center
Location
Houston, United States of America
Timeline & enrollment
Phase
Phase 1/2
Start date
Jun 30, 2023
End date
Sep 30, 2027
Enrollment
60 participants
Primary outcome

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Summary

To find a recommended dose of valemetostat that can be given in combination with rituximab
 and lenalidomide to patients with follicular lymphoma. The safety and effects of this drug
 combination will also be studied

ICD-10 classifications
Hodgkin lymphomaFollicular lymphomaNon-Hodgkin lymphoma, unspecifiedFollicular lymphoma, unspecifiedHodgkin lymphoma, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05683171
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05683171 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by M.D. Anderson Cancer Center and is currently Not yet recruiting. The study focuses on Lymphoma. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.